Loading...
A prior study demonstrated that 99% of patients with chronic hepatitis C virus (HCV) infection achieved sustained virologic response (SVR) after 12 weeks of therapy with the recently approved once-daily, ribavirin-free regimen of the protease inhibitor glecaprevir plus the NS5A inhibitor pibrentasvir (G/P; Lancet Infect Dis 2017; 17:1062).
To evaluate this coformulation's efficacy and safety in HCV genotype 3 patients, investigators conducted an industry-supported, multicenter, partially randomized, open-label, phase III study (SURVEYOR-II Part 3), in which 87 treatment-naive or treatment-experienced cirrhotic patients received G/P for 12 or 16 weeks, respectively. In addition, 44 treatment-experienced noncirrhotic patients — who received pr…